RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a ?26.5 million oversubscribed Series A financing from a broad syndicate ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 ...

SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ('Dermata') and Revance Therapeutics, Inc. (Nasdaq: RVNC) ('Revance' together ...

Researchers swap nitrogen and boron into DNA to create analogues that are geometrically and electrostatically equivalent to ...

A trial team led by Latham’s Mike Morin and David Frazier and Finnegan’s William (Bill) Raich helped Sarepta Therapeutics ...

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...

ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administration (FDA), ...

Company expands sterile fill-finish services, capacity for biologics development and manufacturing, and more pace logo pace ...

UK Biobank has today announced the launch of the world's most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments.

Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company ... afflicted with this terrible disease and their families and made it his life’s cause to help.